<DOC>
	<DOCNO>NCT01636622</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose vemurafenib give combination carboplatin paclitaxel patient advance cancer . The safety study drug combination also study . Vemurafenib design block protein ( call mutate BRAF ) find mole ( spot ) skin certain type cancer cell . This drug may slow growth kill cell . Carboplatin design slow growth cancer cell stop make new DNA ( genetic material cell ) . Paclitaxel design slow growth cancer cell stop divide new cell .</brief_summary>
	<brief_title>Study Vemurafenib , Carboplatin , Paclitaxel</brief_title>
	<detailed_description>Study Groups : If find eligible decide take part , assign study group base join study . Up 8 group 3-6 participant enrol study . The dose vemurafenib dose carboplatin paclitaxel receive depend join study . The first group participant receive low dose level vemurafenib , carboplatin , paclitaxel . Each new group receive high dose level study drug combination group , intolerable side effect see . This continue high tolerable dose combination find . After , 10 additional participant enrol . Study Drug Administration : Each study cycle 3 week . You start take paclitaxel carboplatin Day 1 Cycle 1 . Paclitaxel give vein 3 hour , carboplatin give vein 30-60 minute . You may give medication reduce risk nausea allergic reaction study drug give . Both paclitaxel carboplatin give every 3 week . You start take vemurafenib mouth even Day 1 Cycle 1 . You take vemurafenib twice day , every day start Day 2 Cycle 1 . Study Visits : At every study visit , ask drug may take , feeling , side effect . On Day 1 Cycle 1 : - You physical exam , include measurement weight vital sign do past 8 day . - Your performance status record . - Blood ( 1 tablespoon ) drawn routine test do past 10 day . On Day 8 Cycle 1 : - You physical exam , include measurement vital sign . - Your performance status record . - Blood ( 1 tablespoon ) drawn routine test . On Day 1 Cycles 2 beyond : - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 1 tablespoon ) drawn routine test . - In Cycle 2 , ECG . After Cycle 4 , tolerate study drug combination well study doctor agrees , may Day 1 visit every cycle . Every 6 week ( every 2 cycle ) , CT scan , MRI scan , bone scan , and/or x-ray check status disease . Length Study Participation : You may continue take study drug combination long doctor think best interest . You longer able take study drug disease get bad , start health problem , intolerable side effect occur , unable follow study direction . Your participation study complete End-of-Study Visit . End-of-Study Visit : Within 4 week last dose study drug : - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 1 tablespoon ) drawn routine test . - You ECG . - You CT scan , MRI scan , bone scan , and/or x-ray check status disease . This investigational study . Vemurafenib FDA approve commercially available treat advance melanoma mutate BRAF . Carboplatin paclitaxel FDA approve certain type cancer , include lung ovarian cancer . Using study drug combination treat advance cancer BRAF mutation consider investigational . Up 96 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Patient must age &gt; /= 12 year . 2 . Patient must histologically cytologically confirm diagnosis advance solid tumor lymphoma harbor BRAF mutation , standard therapy available , resistant/refractory standard therapy , relapse standard therapy , standard therapy improve survival least three month . 3 . Patient QTc interval must less 500 msec . 4 . Patient must complete prior cytotoxic chemotherapy radiation therapy least 21 day prior start study drug ( ) , except selective RAF inhibitor ( vemurafenib , dabrafenib LGX818 ) . There washout period prior selective RAF inhibitor . Patients must least 5 halflives 3 week , whichever short , previous target biologic therapy . Local palliative radiation therapy deliver target lesion allow immediately treatment . 5 . Patients must evaluable disease response . 6 . Patient must ECOG performance status 0 2 . 7 . Patient must adequate liver renal function document follow laboratory test result within 14 day prior start therapy : total bilirubin less equal 2 x upper limit normal ( ULN ) ( exception may apply benign nonmalignant indirect hyperbilirubinemia Gilbert syndrome ) ; AST ( SGOT ) ALT ( SGPT ) less equal 2.5 X ULN less equal 5 X ULN liver metastasis present ; serum creatinine less equal 2 X ULN 8 . Patient must adequate bone marrow function document follow laboratory test result within 14 day prior start therapy : platelet great 75,000/mm^3 ; absolute neutrophil count ( ANC ) great 1000/mm^3 ; hemoglobin great 8.0 g/dL 9 . Patient ( man woman ) must agree practice effective contraception entire study period , unless documentation infertility exist , least 4 week last dose study drug ( ) . 10 . Patient must willing able sign inform consent form . 1 . Patients clinically significant illness could compromise participation study , include , limited : active uncontrolled infection ; unstable angina pectoris , myocardial infarction within past 6 month , uncontrolled cardiac arrhythmia . 2 . Patients inability swallow tablet capsule 3 . Patients leptomeningeal disease ; 4 . Patients pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Advanced Cancers</keyword>
	<keyword>Advanced Malignancy</keyword>
	<keyword>BRAF Mutation</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Vemurafenib</keyword>
	<keyword>PLX4032</keyword>
	<keyword>RO5185426</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
</DOC>